healthcare professional
Prof. Benedikt Schoser, MD
Friedrich-Baur-Institute at the Neurological Clinic and Polyclinic,
Ludwig-Maximilians-University Munich,
Munich, Germany
Benedikt Schoser is a professor of neurology at the Friedrich-Baur Institute, Ludwig-Maximilians-University Munich in Germany. He is a specialist in neurology, neurophysiology, neurointensive care, palliative care and myopathology. He serves on the editorial boards of Neuromuscular Disorders, Current Opinion in Neurology, Acta Myologica, and European Journal of Neurology. A fellow of the EAN since 2017, he has been a board member of the educational, Rare Disease, and Scientific Muscle and Neuromuscular panels. Professor Schoser is a World Muscle Society executive board member and organizes the WMS teaching course. Since 2015, he has chaired the European Pompe Consortium (EPOC) and has authored over 350 peer-reviewed publications. His research focuses on multisystemic neuromuscular disorders, myasthenic syndromes, translational research and molecular therapy.
Prof. Vasiliki Zouvelou, MD, PhD
National and Kapodistrian University of Athens,
Eginitio Hospital,
Greece
Vasiliki Zouvelou, a graduate of the National and Kapodistrian University of Athens, Greece, completed her neurology specialization at Evangelismos General Hospital and earned her PhD on “Investigation of Asymptomatic Persistent Hyper-CK-emia” at Eginitio Hospital in Athens. Since 2003, she has worked at the 1st Neurology Department of the University of Athens at Eginitio Hospital, focusing on myasthenia gravis and related neuromuscular disorders. She has led the Outpatient Clinic for Myasthenia Gravis and Related Disorders since 2008. Elected associate professor of neurology-neuroimmunology in January 2023, Dr. Zouvelou has published 90 papers and has delivered over 80 lectures at local and international conferences.
ULTOMIRIS® (ravulizumab) is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody-positive.
Ravulizumab EU Summary of Product Characteristics
Eculizumab EU Summary of Product Characteristics
Prescribing information may differ from country to country. Please refer to your locally approved label and take this into consideration when viewing this information.
Please verify reimbursement status applicable in your country.
Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by contacting: https://contactazmedical.astrazeneca.com/